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Abstract
Purpose: The purpose of this study was to assess the potential of 18F-fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT) imaging for detection of the primary tumor and its impact
on treatment planning in patients presenting with cancer of unknown primary and squamous cell carcinoma
(SCC)-positive cervical lymph nodes of the upper and middle neck.
Methods: The study population consisted of 18 consecutive patients with biopsy-proven SCC involving lymph
nodes of the upper and middle neck region and negative conventional diagnostic procedures with regard to the
location of the primary. All patients underwent FDG-PET/CT according to a standard procedure in search for
the primary, unidentified tumor.
Results: In none of the patients FDG-PET/CT was able to indicate a primary tumor localization. Although FDG-
PET/CT did identify all sites of known lymph node involvement, neither additional sites of lymph node
involvement nor sites of distant metastases were identified. Accordingly, FDG-PET/CT did not impact patient
treatment planning.
Conclusions: In this series, including patients suffering from lymph node metastases by an SCC of unknown
primary in the upper and middle neck, FDG-PET/CT was unable to identify a primary tumor. In addition, FDG-
PET/CT did not modify the treatment planning in any of the patients studied.
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Introduction
Up to 15% of cancer patients present with metastasis froma cancer of unknown primary (CUP).1 Median survival
of patients with CUP and an identified primary site sub-
sequently treated with specific therapy is on average 23
months versus 12 months for those patients in whom the
primary site is not identified.2 Thus, detection of the primary
tumor in CUP patients is of paramount importance.
Cervical lymph nodes are a common site of involvement
in CUP patients. The most commonly encountered histo-
logical diagnosis of CUP with cervical lymph node involve-
ment is squamous cell carcinoma (SCC), followed by
adenocarcinoma.3–5 Cervical lymph node metastases of SCC
origin in the upper and middle neck are generally attributed
to cancers of the head and neck.6 For these patients, routine
workup generally consists of a physical examination, biopsy
or excision of the enlarged lymph nodes, computed tomo-
graphy (CT) and/or magnetic resonance imaging, and pan-
endoscopy.7 With this routine workup, the primary SCC
remains undetected in *2% of patients.8
Previous reports on the usefulness of 18F-fluorodeoxy-
glucose positron emission tomography (FDG-PET) in CUP
patients with negative clinical and conventional diagnostic
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procedures suggest that FDG-PET may detect up to 5%–43%
of the primary tumors missed by clinical and morphological
evaluation.7,9–20 These figures, however, were reported in
series that included patients with CUP and extracervical
metastases as well as varying cancer types, for example,
SCC, adenocarcinoma, melanoma, large cell carcinoma,
plasmocytoma, etc., and the diagnostic performance of FDG-
PET was not determined separately for cervical versus
extracervical CUP presentations and as a function of the
histological subtype. Further, in several of these studies, the
PET methodology was either not standardized or inadequate
and most of these studies were conducted using FDG-PET
and not FDG-PET/CT, which might have resulted in a
higher rate of false-positive findings and sensitivity.
In this study, the potential of FDG-PET/CT imaging for
detection of the primary tumor and its impact on treatment
planning in patients presenting with CUP and SCC-positive
cervical lymph nodes of the upper and middle neck were
assessed.
Patients and Methods
Between November 2002 and November 2007, patients
presenting to the Department of Head and Neck Surgery of
University Hospital of Gent, Belgium, with metastatic SCC of
the upper and middle neck were included in this study.
All patients had routine workup with medical history and
physical examination including rigid endoscopy of the nasal
cavity and nasopharynx and flexible fiber-endoscopy of the
oropharynx, hypopharynx, and larynx. Contrast-enhanced
high-resolution computed tomography of the neck (slice
thickness of 3mm) and the thorax (spiral scanning) was
performed in all patients. Fine-needle aspiration cytology or
histology of the metastatic lymph nodes proved the presence
of metastatic SCC. In all selected patients, neither clinical
examination nor computer tomography was able to put
forward a possible primary tumor localization.
Next, all patients underwent a full-body FDG-PET/CT to
guide eventual biopsies in the following planned panendo-
scopy under general anesthesia. FDG-PET/CT was per-
formed according to the standard protocol at the Ghent
University Hospital. The patients fasted at least 4 hours prior
to intravenous injection of F-18 FDG (3.7MBq/kg body
weight). Blood glucose levels were checked prior to the in-
jection of F-18 FDG and did not exceed 140mg/dL. If not
contraindicated, iodinated intravenous contrast (iohexol,
350mg iodine/mL [GE Healthcare, Diegem, Belgium], or
iomeprol, 400mg iodine/mL [Bracco Imaging Europe,
Waver, Belgium]) was administered immediately before CT
scanning. Patients were imaged with the Gemini PET-CT
imaging system (Philips Co., Cleveland, OH), which consists
of a gadolinium oxyorthosilicate full-ring PET scanner with
5.0mm spatial resolution and a 16-slice helical CT scanner.
After a 60-minute uptake period, during which patients were
instructed to rest silently, images were acquired. First, a CT
surview (30mA, 120 kV, FOV 500mm, collimation 0.75mm)
was performed from the base of the skull through the mid
thigh. This was followed by a low-dose CT (30mA, 120 kV,
FOV 500mm, 0.5 seconds rotation time, pitch 0.9, collimation
16 · 1.5mm) and a high-quality CT (150mA, 120 kV, FOV
500mm, 0.5 seconds rotation time, pitch 0.9, collimation
16 · 1.5mm, slice thickness and increment 5mm) without
specific breath-holding instructions and arms at the side of
the torso. PET scanning was performed immediately after
acquisition of the CT images, without changing the patient
position. Images were acquired from the base of the skull to
the proximal half of the femora. PET images were re-
constructed using an iterative 3D-RAMLA (Row Action
Maximum Likelihood Algorithm) provided by the vendor.
Low-dose CT data were used for attenuation correction.
Two skilled nuclear medicine physicians and radiologists
who were unaware of the clinical findings evaluated FDG-
PET/CT results. In cases of discrepancy, the FDG-PET/CT
interpretation was reached by consensus. In case of positive
FDG-PET/CT findings, surgery or biopsy was required to
confirm that positive findings were indeed related to the
presence of a primary tumor. If the FDG-PET/CT findings
were negative, long-term follow-up was used to confirm the
initial negative findings.
Results
Eighteen consecutive patients were included in the study.
There were 16 men and 2 women with a mean age of 58.8
years (range: 45.8–78.7 years). The metastatic lymph nodes
were located in neck regions II or III or overlapped both
regions. Nine lymph nodes were smaller than 3 cm in di-
ameter, six were larger than 3 cm but smaller than 6 cm in
diameter, and three were larger than 6 cm in diameter. Nine
patients presented with solitary metastatic lymph node in-
volvement, whereas in the remaining 9 patients multiple
lymph nodes were involved. According to the UICC 1997
TNM classification, the N-stage of the study patients was N1
in 3, N2a in 4, N2b in 7, N2c in 1, and N3 in 3 patients.
Although all known sites of lymph node involvement
were visualized, in none of the patients included did FDG-
PET/CT examinations demonstrate a primary tumor. Ad-
ditionally, in none of the patients additional lymph nodes or
distant metastases that could have impacted the therapeutic
decision-making were detected.
Patients were treated with a combination of therapies ac-
cording to the oncologic guideline of the Ghent University
Hospital: 4 patients had primary radiotherapy, 9 patients
had surgery and adjuvant postoperative radiotherapy, 2
patients had surgery and postoperative concomitant radio-
chemotherapy (platinum based), and 3 patients had
concomitant radiochemotherapy (platinum based). The ra-
diation therapy was intensity modulated with a total dose of
70 Gy and covered the complete mucosa of the upper air-
way. The chemotherapy was based on cisplatinum at a dose
of 100mg/m2 and given on days 1, 22, and 43 of the radio-
therapy.
With a median follow-up time of 32 months, 10 patients
remained alive without evidence of disease, 6 patients died
of their disease (all due to distant metastatic disease), and 2
patients were lost to follow-up. Follow-up did not reveal a
primary tumor in any of the patients studied, neither by
regular clinical examination nor by CT scanning.
Discussion
Finding the primary tumor site in patients presenting with
SCC involving cervical lymph nodes of the upper and mid-
dle neck presents a diagnostic and therapeutic dilemma. To
minimize cosmesis while curing the tumor in these patients,
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surgery, with or without selective radiation therapy, is the
treatment of choice.1–3 However, if the primary tumor is not
identified, usually, generalized radiation therapy is admin-
istered, which includes the naso-, oro-, and hypopharynx,
sometimes with debilitating effects. Further, survival is sig-
nificantly better for those patients in whom the primary can
be identified.
Following thorough clinical examination and morpho-
logical imaging, the primary tumor remains undetected in
< 2% of patients with cervical lymph node metastases of an
SCC, explaining the limited number of patients included in
this series and other studies available on this topic.8 Al-
though, in this series, FDG-PET/CT identified all known
neck metastases, confirming the FDG avidity of SCC, this
imaging modality proved to be unable to identify a primary
tumor in any of the patients under study. This finding may
be attributed to several causes. First, the size of the lesion as
well as the degree of FDG uptake may have been too low
and thus, because of the limited spatial resolution and re-
lated partial volume effect of PET systems, the lesion may
have passed undetected.21 More recently, time-of flight PET
machines were introduced in the market.22,23 These machines
allow for the registration of the actual time difference be-
tween the arrival of the annihilation photons in the detectors.
Incorporation of this information in the reconstruction al-
gorithm improves the spatial resolution. Thus, in the future,
studies comparing conventional PET with TOF-PET for the
detection of SCC CUP in the upper and middle neck may
prove of interest. Second, it has been hypothesized that an-
giogenic incompetent primary tumors may remain very
small, under the detection limit of the system, and even
undergo apoptosis following the metastatic process.24 In this
regard, it was found that in cases of SCC involving the head
and neck, the primary tumors, uninvolved mucosa, and
metastatic lymph nodes had significantly lower total blood
vessels counts than the nonmetastatic cervical lymph
nodes.25 Further, in the same study, neoangiogenesis proved
much lower in metastatic lymph nodes when compared with
the primary tumor, suggesting that the growth of tumors in
the metastatic lymph nodes is independent of angiogenesis;
lymph node metastases occupy well-vascularized lymph
nodes, and lymph sinuses are rich in nutrients. Obviously, if
the lesions are no longer there because of spontaneous apo-
ptosis, it cannot be detected.
At first glance, the findings of the present study are in
sharp contrast with results reported in a recent meta-analysis
performed by Kwee et al. on the potential of combined PET/
CT for the detection of CUP.26 In this meta-analysis, overall
FDG-PET/CT was able to detect 37% of primary tumors in
patients with CUP, respectively, with a sensitivity and
specificity of 84%. The most commonly detected location of
the primary tumor by FDG-PET/CT was the lung (33%),
and the most common locations of false-positive findings
were the lung and oropharynx. Importantly, the sensitivity
proved heterogeneous across studies, and subgroup analysis
was unable to offer additional information in this regard. In 7
of 11 studies included, the location of the sites of metastases
was cervical as well as extracervical, and in 3 of 4 of the
remaining studies, minimally three different histological
subtypes of metastatic sites were included. Only one study
included, by Fakhry et al., reported on a series of 22 patients
suffering from SCC involving lymph nodes from CUP.27 In
this series, adopting a similar strategy to ours, FDG-PET/CT
detected 4 primary tumors that were not detected by routine
staging. Because of limited patient details in this study, direct
comparison of the present study with the study by Fakhry
et al. is not possible. For instance, it would have been in-
teresting to identify whether sites of lymph node involve-
ment, respectively, upper, middle versus lower cervical,
were different between both studies and also whether the
extent of lymph node involvement was different between
those patients in whom a primary was detected versus those
in whom no primary was identified.
Aside from the search for an unidentified primary, in the
present study, the potential therapeutic impact of FDG-PET/
CT was also addressed. Four studies have previously re-
ported on the therapeutic impact of FDG-PET/CT in CUP
patients.27–30 In these studies, FDG-PET/CT modified ther-
apy in 18.2%–60% of patients. For instance, in the series by
Fakhry et al. in 4 patients in whom FDG-PET/CT identified
the primary tumor, the size of the radiation fields could
be reduced and thus also morbidity.27 These reports are
in sharp contrast with the findings of the present study;
aside from the lack of detection of a primary tumor, no ad-
ditional sites of lymph node involvement or distant metas-
tases that could have influenced the treatment planning were
detected.
Finally, whether or not FDG-PET/CT also impacts patient
outcome in CUP patients is an issue that needs to be ex-
plored. To date, only one study, by Fencl et al., suggested
that FDG-PET/CT in CUP patients might indeed affect
outcome.31 In this series, the survival rate of CUP patients
with at least one hypermetabolic lesion proved significantly
lower when compared with the remaining CUP patients.
Additional studies addressing this issue are warranted.
Conclusions
To conclude, in this series, including only patients suf-
fering from lymph node metastases by an SCC of unknown
primary in the upper and middle neck, FDG-PET/CT proved
to be unable to identify the primary tumor. In addition, FDG-
PET/CT did not modify the treatment planning in any of the
patients studied.
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